SDC1 and AL amyloidosis: mAbs in multiple myeloma have been generated against CD38, CD40, CD56, CD74, CD138, SLAMF7, KIR, and PD-1 target antigens, two of which are applicable and FDA-approved for treating patients with MM, including daratumumab (Anti-CD38 mAb) and elotuzumab (Anti-SLAMF7 MAb) [21].